GlassScriptPhysician profile
David C Mishkel
NPI 1407991839
$4,001.88
in general payments reported to CMS, 2019-2025
34 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,365 · 2021: $379 · 2022: $119 · 2023: $200 · 2024: $207 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $349.44 | 2019-2025 | |
| Abbott Laboratories | $337.27 | 2019-2025 | Aveir, Diamondback Peripheral, Amplatzer Amulet |
| E.R. Squibb & Sons, L.L.C. | $280.09 | 2019-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $264.56 | 2019 | |
| Pfizer INC. | $252.20 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $232.25 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.19 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $219.28 | 2019-2021 | |
| Amgen INC. | $187.78 | 2019-2025 | Repatha |
| Novo Nordisk INC | $175.39 | 2024-2025 | Ozempic, Wegovy |
| Cleerly, INC. | $148.59 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Medtronic, INC. | $137.47 | 2021-2025 | Micra |
| Astellas Pharma US INC | $136.89 | 2019 | |
| Atricure, INC. | $111.87 | 2024 | |
| Kestra Medical Technology Services, INC. | $110.22 | 2025 | Assure Wcd |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $101.38 | 2025 | Watchman Flx, Versacross Access Solution |
| Cardiva Medical, INC. | $79.71 | 2022-2023 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 5f Vcs |
| Merck Sharp & Dohme LLC | $72.00 | 2025 | Verquvo |
| Philips North America LLC | $66.78 | 2019 | |
| Alnylam Pharmaceuticals INC. | $59.80 | 2019-2025 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $56.62 | 2019 | |
| Chiesi USA, INC. | $53.78 | 2019-2025 | Kengreal |
| Amarin Pharma, INC. | $48.13 | 2019 | |
| Bridgebio Pharma, INC. | $43.80 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.81 | 2019-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $39.82 | 2025 | |
| Medtronic Vascular, INC. | $35.03 | 2019 | |
| Lilly USA, LLC | $26.07 | 2025 | Zepbound, Mounjaro |
| Actelion Pharmaceuticals US, INC. | $25.56 | 2025 | Opsumit |
| Biotronik INC. | $18.20 | 2024 | |
| Tactile Systems Technology INC | $17.25 | 2025 | Nimbl, Flexitouch Plus |
| Esperion Therapeutics, INC. | $14.95 | 2025 | Nexletol |
| Inspire Medical Systems, INC. | $14.46 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mishkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.